Gleevec Buoyed By GIST Trial Results; Novartis Will Seek Adjuvant Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
NCI-sponsored study halted after imatinib meets primary endpoint, rate of recurrence-free survival, in Kit-positive GIST patients.